What happened
- REMODEL‑1 and REMODEL‑2 randomly assigned 2,007 people with relapsing MS to remibrutinib (a BTK inhibitor, Novartis) or teriflunomide, an existing oral drug.
- Annual relapse rates were lower with remibrutinib: 0.073 versus 0.112, and 0.080 versus 0.116 (rate ratios 0.65 and 0.69). Published in The Lancet.
- Fewer people stopped remibrutinib because of side effects (3.1% vs 5.8%), and the authors report no liver safety concerns.
What we don't know yet
- The trials are ongoing; long-term disability results are not in yet.
- It is not approved for MS. Comparison was with teriflunomide, not the strongest MS drugs.
Primary sources
- The Lancet: Remibrutinib versus teriflunomide (REMODEL‑1 and REMODEL‑2)Peer-reviewed journal
- PubMed abstract 42915009Peer-reviewed journal
Not medical advice. This is a summary of published results, not a recommendation. Ask your own doctor whether any treatment or trial fits you. To look for trials near you, search ClinicalTrials.gov or the WHO trial registry portal.